SK Bioscience Co Ltd
KRX:302440

Watchlist Manager
SK Bioscience Co Ltd Logo
SK Bioscience Co Ltd
KRX:302440
Watchlist
Price: 53 000 KRW -1.85% Market Closed
Market Cap: 4.2T KRW

SK Bioscience Co Ltd
Cash Taxes Paid

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

SK Bioscience Co Ltd
Cash Taxes Paid Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Taxes Paid CAGR 3Y CAGR 5Y CAGR 10Y
SK Bioscience Co Ltd
KRX:302440
Cash Taxes Paid
â‚©4.7B
CAGR 3-Years
-20%
CAGR 5-Years
-9%
CAGR 10-Years
N/A
Celltrion Inc
KRX:068270
Cash Taxes Paid
â‚©298B
CAGR 3-Years
11%
CAGR 5-Years
33%
CAGR 10-Years
37%
V
Voronoi Inc
KOSDAQ:310210
Cash Taxes Paid
â‚©142.4m
CAGR 3-Years
422%
CAGR 5-Years
88%
CAGR 10-Years
N/A
P
PharmaResearch Co Ltd
KOSDAQ:214450
Cash Taxes Paid
â‚©33.1B
CAGR 3-Years
40%
CAGR 5-Years
58%
CAGR 10-Years
28%
Alteogen Inc
KOSDAQ:196170
Cash Taxes Paid
â‚©3.3B
CAGR 3-Years
102%
CAGR 5-Years
96%
CAGR 10-Years
56%
A
ABL Bio Inc
KOSDAQ:298380
Cash Taxes Paid
â‚©101.9m
CAGR 3-Years
N/A
CAGR 5-Years
-8%
CAGR 10-Years
N/A
No Stocks Found

SK Bioscience Co Ltd
Glance View

Market Cap
4.2T KRW
Industry
Biotechnology

SK Bioscience Co Ltd., a remarkable enterprise carved out of the South Korean corporate landscape, operates at the dynamic intersection of biotechnology and pharmaceuticals. A part of the larger SK Group, one of Korea's leading conglomerates, the company was officially established in 2018 from SK Chemicals' life sciences division. Its primary focus is on developing and manufacturing vaccines, serving both public health needs locally and globally. The company has swiftly gained prominence for its role in the COVID-19 pandemic, particularly with the production of vaccines in collaboration with significant players such as AstraZeneca and Novavax. This strategic engagement loop has positioned SK Bioscience not only as a critical player in health crises management but also as a pivotal contributor to global health security. At the heart of SK Bioscience's business model is its ability to leverage cutting-edge research and robust manufacturing capabilities. The firm generates revenue through various channels, including product sales of its vaccines and other pharmaceuticals, contract manufacturing services, and partnerships with global entities, allowing it a diversified income stream. Its adeptness in innovation, underpinned by a strong R&D framework, ensures a steady development pipeline, supporting long-term growth ambitions. Through these strategic activities, SK Bioscience aligns itself with the SK Group’s broader commitment to social value and environmental, social, and governance (ESG) principles, fortifying its reputation as a company that not only seeks financial success but also endeavors to wield a positive global impact.

SK Bioscience Co Ltd Intrinsic Value
HIDDEN
Show

See Also

What is SK Bioscience Co Ltd's Cash Taxes Paid?
Cash Taxes Paid
4.7B KRW

Based on the financial report for Dec 31, 2024, SK Bioscience Co Ltd's Cash Taxes Paid amounts to 4.7B KRW.

What is SK Bioscience Co Ltd's Cash Taxes Paid growth rate?
Cash Taxes Paid CAGR 5Y
-9%

Over the last year, the Cash Taxes Paid growth was -82%. The average annual Cash Taxes Paid growth rates for SK Bioscience Co Ltd have been -20% over the past three years , -9% over the past five years .

Back to Top